Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Altria-Juul Labs deal: why did it occur and what does it mean for the US nicotine delivery product market.

Levy DT, Sweanor D, Sanchez-Romero LM, O'Connor R, Goniewicz ML, Borland R.

Tob Control. 2019 Sep 4. pii: tobaccocontrol-2019-055081. doi: 10.1136/tobaccocontrol-2019-055081. [Epub ahead of print] No abstract available.

2.

Do not damn tobacco users to ignorance about big differences in deadly products because you disapprove of the 'bus' they are on.

Kozlowski LT, Sweanor DT.

Addict Behav. 2018 Feb;77:287-288. doi: 10.1016/j.addbeh.2017.04.008. Epub 2017 Apr 6. No abstract available.

PMID:
28410776
3.

'Not harmless' messages without comparisons disserve consumers, potential consumers, and public health approaches to tobacco/nicotine products.

Kozlowski LT, Sweanor DT.

Addict Behav. 2018 Jan;76:390-391. doi: 10.1016/j.addbeh.2017.01.030. Epub 2017 Jan 25. No abstract available.

PMID:
28153393
4.

Young or adult users of multiple tobacco/nicotine products urgently need to be informed of meaningful differences in product risks.

Kozlowski LT, Sweanor DT.

Addict Behav. 2018 Jan;76:376-381. doi: 10.1016/j.addbeh.2017.01.026. Epub 2017 Jan 25. Review.

5.

Withholding differential risk information on legal consumer nicotine/tobacco products: The public health ethics of health information quarantines.

Kozlowski LT, Sweanor D.

Int J Drug Policy. 2016 Jun;32:17-23. doi: 10.1016/j.drugpo.2016.03.014. Epub 2016 Apr 1.

6.

E-cigarettes are less harmful than smoking.

Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerstrom K, Letlape K, Polosa R, Ramsey J, Sweanor D.

Lancet. 2016 Mar 19;387(10024):1160-2. doi: 10.1016/S0140-6736(15)00253-6. No abstract available.

PMID:
27025332
7.

Smoking, vaping and public health: Time to be creative.

Sweanor D.

Can J Public Health. 2016 Mar 16;106(8):e464-6. doi: 10.17269/cjph.106.5389.

PMID:
26986903
8.

Big tobacco, E-cigarettes, and a road to the smoking endgame.

Branston JR, Sweanor D.

Int J Drug Policy. 2016 Mar;29:14-8. doi: 10.1016/j.drugpo.2015.12.023. Epub 2015 Dec 29.

PMID:
26774225
9.

Differential Taxes for Differential Risks--Toward Reduced Harm from Nicotine-Yielding Products.

Chaloupka FJ, Sweanor D, Warner KE.

N Engl J Med. 2015 Aug 13;373(7):594-7. doi: 10.1056/NEJMp1505710. No abstract available.

PMID:
26267620
10.

Public health and electronic cigarettes.

Sweanor D.

Can J Respir Ther. 2014 Summer;50(2):41-2. No abstract available.

11.

What to consider when regulating electronic cigarettes: Pros, cons and unintended consequences.

Caponnetto P, Saitta D, Sweanor D, Polosa R.

Int J Drug Policy. 2015 Jun;26(6):554-9. doi: 10.1016/j.drugpo.2015.03.001. Epub 2015 Mar 14.

PMID:
25857204
12.

Estimating the harms of nicotine-containing products using the MCDA approach.

Nutt DJ, Phillips LD, Balfour D, Curran HV, Dockrell M, Foulds J, Fagerstrom K, Letlape K, Milton A, Polosa R, Ramsey J, Sweanor D.

Eur Addict Res. 2014;20(5):218-25. doi: 10.1159/000360220. Epub 2014 Apr 3.

13.

Should e-cigarettes be regulated as a medicinal device?

Hajek P, Foulds J, Le Houezec J, Sweanor D, Yach D.

Lancet Respir Med. 2013 Aug;1(6):429-31. doi: 10.1016/S2213-2600(13)70124-3. Epub 2013 Jul 23. No abstract available.

PMID:
24429230
14.

Looking for the next breakthrough in tobacco control and health.

Sweanor D, Yach D.

S Afr Med J. 2013 Sep 30;103(11):810-1. doi: 10.7196/samj.7513. No abstract available.

PMID:
24148163
15.

Effective beats dramatic: a commentary on Australia's plain packaging of cigarettes.

Sweanor DT.

Drug Alcohol Rev. 2011 Nov;30(6):683-4. doi: 10.1111/j.1465-3362.2011.00370.x. Epub 2011 Sep 23. No abstract available.

PMID:
21950489
16.

The case for OFSMOKE: how tobacco price regulation is needed to promote the health of markets, government revenue and the public.

Gilmore AB, Branston JR, Sweanor D.

Tob Control. 2010 Oct;19(5):423-30. doi: 10.1136/tc.2009.034470.

17.

Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

O'Connor RJ, Cummings KM, Rees VW, Connolly GN, Norton KJ, Sweanor D, Parascandola M, Hatsukami DK, Shields PG.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3334-48. doi: 10.1158/1055-9965.EPI-09-0429. Review.

18.

Beneficence or maleficence--Big Tobacco and smokeless products.

McNeill A, Sweanor D.

Addiction. 2009 Feb;104(2):167-8. doi: 10.1111/j.1360-0443.2008.02483.x. No abstract available.

PMID:
19149806
19.

Tobacco harm reduction: how rational public policy could transform a pandemic.

Sweanor D, Alcabes P, Drucker E.

Int J Drug Policy. 2007 Mar;18(2):70-4. Epub 2007 Jan 5.

PMID:
17689347
20.

Advice on using over-the-counter nicotine replacement therapy-patch, gum, or lozenge-to quit smoking.

Kozlowski LT, Giovino GA, Edwards B, Difranza J, Foulds J, Hurt R, Niaura R, Sachs DP, Selby P, Dollar KM, Bowen D, Cummings KM, Counts M, Fox B, Sweanor D, Ahern F.

Addict Behav. 2007 Oct;32(10):2140-50. Epub 2007 Feb 3.

PMID:
17360126
21.

The potential impact of a low-nitrosamine smokeless tobacco product on cigarette smoking in the United States: estimates of a panel of experts.

Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino GA, Hyland A, Sweanor D, Warner KE, Compton C.

Addict Behav. 2006 Jul;31(7):1190-200. Epub 2005 Oct 26.

PMID:
16256276
22.

The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts.

Levy DT, Mumford EA, Cummings KM, Gilpin EA, Giovino G, Hyland A, Sweanor D, Warner KE.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2035-42.

23.

Legal strategies to reduce tobacco-caused disease.

Sweanor D.

Respirology. 2003 Dec;8(4):413-8. Review.

PMID:
14708550
24.

Reducing toxicity exposure for the nicotine-dependent.

Sweanor D.

Addiction. 2003 Sep;98(9):1197-8; discussion 1204-7. No abstract available.

PMID:
12930203
25.

Is it the nicotine or the tobacco?

Sweanor D.

Bull World Health Organ. 2000;78(7):943. No abstract available.

26.

World's best practice in tobacco control.

Laugesen M, Scollo M, Sweanor D, Shiffman S, Gitchell J, Barnsley K, Jacobs M, Giovino GA, Glantz SA, Daynard RA, Connolly GN, Difranza JR.

Tob Control. 2000 Jun;9(2):228-36. No abstract available.

27.

Regulatory imbalance between medicinal and non-medicinal nicotine.

Sweanor D.

Addiction. 2000 Jan;95 Suppl 1:S25-8. Review.

PMID:
10723819
28.

Policy options to reduce tobacco-caused mortality.

Sweanor DT.

J Addict Dis. 1999;18(3):1-11. Review.

PMID:
10507577
29.

Cigarette taxes.

Scollo M, Sweanor D.

Tob Control. 1999 Spring;8(1):110-1. No abstract available.

30.

The emerging market for long-term nicotine maintenance.

Warner KE, Slade J, Sweanor DT.

JAMA. 1997 Oct 1;278(13):1087-92.

PMID:
9315768
31.

Tobacco taxes: the Canadian experience.

Sweanor DT.

Alaska Med. 1996 Jan-Mar;38(1):40-1. No abstract available.

PMID:
8936105
32.

Killing taxes and Canadians.

Sweanor D.

Can J Public Health. 1994 Mar-Apr;85(2):78-80. English, French. No abstract available.

PMID:
8012921

Supplemental Content

Loading ...
Support Center